With the commencement of enrolment for the pivotal Phase III HONOR study of TNX-102 SL in military-related post-traumatic stress disorder (PTSD), the future of Tonix is squarely in its hands. The study is expected to enroll up to 550 patients with a CAPS-5 of ≥33 upon entry. Importantly, the FDA has agreed to an interim analysis encompassing 275 patients at which point it may be stopped for efficacy. The FDA has also indicated that if the data are “statistically persuasive” only one study may be needed for approval. The interim analysis is expected in H118 with full data in H218.

Continue reading

This version is programmatically created by Research Central and qualified in its entirety to the original PDF.

Powered by Research Central